Alzheimer's Drug Discovery Foundation - Preclinical Drug Discovery RFP 2015 ($ 150,000)

The Alzheimer's Drug Discovery Foundation (ADDF) invites applications for the Preclinical Drug Discovery funding mechanisms. The upcoming deadline for submission of a full proposal is September 22, 2015. The Letter of Intent is due two weeks before the proposal deadline. Funding averages $150,000 per year.

The funding mechanisms are the following:
• Academic Program seeks to create and support innovative translational programs in academic medical centers and universities;
• Biotechnology Development Program supports qualified scientific projects in existing, private, early-stage biotechnology companies. The ADDF will provide support for qualified projects in more advanced companies if a clear need for non-profit funding to support the project can be demonstrated and justified. Funding is typically made as a program-related investment;
• Biotechnology Founders Technology Transfer Program supports academic programs that are eligible for technology transfer and the start-up of new biotechnology companies. Up to 35% of funds from these awards may be employed for expenses related to company formation, such as administrative, legal, patent and third-party vendor costs.

The 2015 Preclinical research funding priorities are:
• Drug Discovery - Target validation, high throughput screening, medicinal chemistry - including hit to lead development and lead optimization-, in vitro and in vivo efficacy studies, ADME, toxicology, pharmacokinetics and pharmacodynamics, and in vivo proof-of-concept with lead compounds and biologics;
• Biomarker Development - Development of blood, CSF, and imaging biomarkers to accelerate clinical trials, allow for accurate and early diagnosis, and to track disease progression.expenses related to company formation, such as administrative, legal, patent and third-party vendor costs.

ADDF funds drug discovery research programmes from investigators in academia and biotechnology companies. In addition, ADDF initiates, sponsors, and co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation, bringing together physicians, scientists, and policy makers worldwide.